<DOC>
	<DOCNO>NCT00355849</DOCNO>
	<brief_summary>A study evaluate efficacy safety Human Insulin Inhalation Powder [ also know AIR® Inhaled Insulin ] [ AIR® register trademark Alkermes , Inc . ] patient Type 2 diabetes currently treat daily insulin glargine injection . The present study intend determine mealtime AIR® Insulin may superior once-daily insulin glargine injection .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus one oral antihyperglycemic medication oncedaily insulin glargine HbA1c great equal 7.5 less equal 10.5 % Nonsmoker take TZD dose great indicate two episode severe hypoglycemia 6 month prior Have low respiratory infection 3 month prior systemic glucocorticoid therapy clinical sign symptom liver disease , acute chronic hepatitis history renal transplantation Have active untreated malignancy Require 150 U/day insulin glargine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>